Blockbuster Sanofi & Regeneron Drug Dupixent Notches FDA Nod for an Inflammatory Skin Disease
Sanofi and Regeneron Pharmaceuticals drug Dupixent has won FDA approval for chronic spontaneous urticaria, introducing a new approach to the ...
Thursday, May 1, 2025
Tag: Sanofi
Sanofi’s chief digital officer says remote work means employees lose the ‘serendipity’ needed to innovate
© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use ...
1 Dividend Stock Down 30% to Buy and Hold for the Next Decade
Biotech giant Regeneron Pharmaceuticals (Nasdaq: rain) saw its fortunes reversed last year. Though the drugmaker had performed well since the ...
Sanofi Drug for Rare Blood Disease Is Heading to Recordati for $825M
Sanofi’s Enjaymo, the only approved drug therapy for a rare and debilitating blood disorder, is being acquired by Recordati in ...
Sanofi and Regeneron Biologic Drug Dupixent Notches a New FDA Approval in COPD
The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval ...
Explore Israel's diverse narratives with The Israel Chronicle. Stay informed with unbiased reporting, insightful analysis, and comprehensive coverage of politics, culture, technology, and more. Discover the heartbeat of Israel through our trusted news platform.